The Effect of Single Lung Ventilation Duration on Postoperative Pulmonary Complications in Thoracic Surgery

Condition(s) studied

Investigational drug(s) / intervention(s)

One-Lung ventilation: In this observational study, the naturally occurring duration of intraoperative single-lung ventilation (SLV) during thoracic surgery will be recorded. No intervention is applied or modified for research purposes. The exposure of interest is the total duration (in minutes) of SLV, which will be timed from initiation to termination during surgery. This variable will be analyzed in relation to postoperative pulmonary complications.

Study summary

This observational study investigates the relationship between the duration of single-lung ventilation (SLV) and the incidence of postoperative pulmonary complications (PPCs) such as pneumonia, pneumothorax, hemothorax, acute lung injury, and acute respiratory distress syndrome (ARDS) in adult patients undergoing thoracic surgery. A total of 134 patients aged 18-85 years, scheduled for thoracic surgery requiring SLV, will be monitored. Data including SLV duration, perioperative parameters, and postoperative pulmonary outcomes will be analyzed.

Eligibility

Primary outcome measure(s)

• Postopertive Pulmonary Complications — postoperative 7 days
  Postoperative pulmonary complications (PPCs) are defined as respiratory events occurring within the first seven days following thoracic surgery, which negatively impact patient outcomes. In this study, PPCs include pneumonia, pneumothorax, hemothorax, acute lung injury, acute respiratory distress syndrome (ARDS), prolonged oxygen requirement, unplanned reintubation, and the need for non-invasive ventilation. These complications will be identified through clinical assessment, arterial blood gas analysis, and postoperative imaging such as chest X-rays. Each case will be evaluated using predefined diagnostic criteria to ensure consistency. The incidence of PPCs will be analyzed in relation to the duration of intraoperative single-lung ventilation.

Trial sites (1)

More Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital trials in Turkey

Other trials for the same condition